|Bid||1.490 x 4000|
|Ask||1.500 x 3200|
|Day's Range||1.470 - 1.515|
|52 Week Range||0.910 - 2.780|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
-Lead Investigational New Drug program for Alpha-1-antitrypsin deficiency received FDA’ s orphan drug designation and is on track for commencing IND-enabling studies in fiscal 2019. -Second IND-track program ...
LONDON, UK / ACCESSWIRE / May 31, 2018 / If you want a free Stock Review on ONVO sign up now at www.wallstequities.com/registration. Durham, North Carolina headquartered IQVIA Holdings Inc.'s stock finished Wednesday's session 1.31% higher at $100.48 with a total trading volume of 968,866 shares. Over the last month and the previous three months, the Company's shares have advanced 4.93% and 2.19%, respectively.
NEW YORK, May 16, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Tyson ...
Organovo Holdings, Inc. (ONVO) (“Organovo”) will host a conference call on Thursday, May 31, 2018 at 5:00 p.m. Eastern Time (ET) to discuss the Company's fiscal fourth-quarter 2018 financial results. In advance of the call on May 31, 2018, Organovo will issue its fiscal fourth-quarter 2018 earnings press release, which will be available at http://www.organovo.com.
Organovo Holdings, Inc. (ONVO) (“Organovo”) today announced that it will present new preclinical data showing the strong functionality of its liver therapeutic tissue in a second IND-track program for Type 1 Tyrosinemia. This data will be presented at the World Advanced Therapies and Regenerative Medicine Congress in London on May 18, 2018 by Benjamin Shepherd, Ph.D., Senior Director of Therapeutics, at Organovo. Type 1 Tyrosinemia is a rare disease characterized by a patient’s inability to metabolize the amino acid tyrosine due to a deficiency of the enzyme fumarylacetoacetate hydrolase. This disorder frequently causes severe liver damage, with current treatment options often limited to organ transplantation. Organovo recently studied the potential benefit of its NovoTissues® in an established animal model for Type 1 Tyrosinemia, and showed retention and sustained functionality post-implamantation. Pathologic evaluation of the diseased animals receiving implanted bioprinted liver tissues also suggested an improvement in liver health and extended survival versus non-treated animals.
Approximately $80 million from the federal government will be combined with more than $200 million in cost share to support the development of tissue and organ manufacturing capabilities. As part of continuing efforts to help revitalize American manufacturing and incentivize companies to invest in new technology development in the United States, ARMI will lead BiofabUSA on behalf of the Department of Defense. Under the umbrella of Manufacturing USA, a public-private network that invests in the development of world-leading manufacturing technologies, ARMI will work to integrate and organize the fragmented collection of industry practices and domestic capabilities in tissue Biofabrication technology to better position the US relative to global competition. ARMI will also focus on accelerating regenerative tissue research and creating state-of-the-art manufacturing innovations in biomaterial and cell processing for critical Department of Defense and civilian needs.
SAN DIEGO, April 16, 2018-- Organovo Holdings, Inc. today announced that along with its collaborators, it has achieved several breakthrough capabilities for its 3 D bioprinted tissues. At last week’ s ...
SAN DIEGO, April 12, 2018-- Organovo Holdings, Inc. today presented data on modeling non-alcoholic fatty liver disease using its 3 D bioprinted human liver tissues. This data was presented at The International ...
Late-Breaking Poster Presented at The International Liver Congress SAN DIEGO and KALAMAZOO, Mich. , April 12, 2018 /PRNewswire/ -- Cirius Therapeutics announced today that it presented a late-breaking ...
SAN DIEGO, March 26, 2018-- Organovo Holdings, Inc. today announced that its wholly-owned subsidiary, Samsara Sciences, Inc., a provider of highly specialized human liver cells, entered a non-exclusive ...
NEW YORK, NY / ACCESSWIRE / February 8, 2018 / Organovo Holdings, Inc. (NASDAQ: ONVO ) will be discussing their earnings results in their Q3 Earnings Call to be held on February 8, 2018 at 5:00 PM Eastern ...
NEW YORK, NY / ACCESSWIRE / August 9, 2017 / Organovo Holdings, Inc. (NASDAQ: ONVO ) will be discussing their earnings results in their Q1 Earnings Call to be held on Wednesday, August 9, 2017 at 5:00 ...